Medical Countermeasures
Swift, Effective, Flexible
MRIGlobal accelerates the discovery and development of broad-spectrum medical countermeasures to prevent or mitigate the adverse health effects resulting from chemical threat agents, infectious disease, and bioterrorism.
- Chemical Warfare Agents
- Toxic Industrial Chemicals
- Emerging Chemical Threats
Biological Medical Countermeasures
- Emerging Infectious Disease
- Infectious Disease
- Biological Warfare
- Antimicrobial Resistance
Contact
Ed Sistrunk
816-326-5650
Request Information
Featured Work
MRIGlobal Supports Global Health with BARDA Medical Countermeasures Development
Under the 5-year, Indefinite Delivery/Indefinite Quantity contract with a potential value of up to $100 million, MRIGlobal will support BARDA's mission to develop medical countermeasures and supportive reagents and assays against chemical threat agents for regulatory acceptance in the U.S. “MRIGlobal has a rich history of providing innovative science and technology solutions to BARDA and we are honored to continue…
Upcoming Events
Unique Facilities and Offerings
- More than 276 linear feet of hood capacity (twice that of the leading competitor)
- Highly secure Chemical Containment and Animal Exposure facilities
- Unrestricted access to DoD and non-DoD chemical agents
- Technical staff with extensive experience in SOP development, safety, ISO and GLP procedure
- Ocular
- Skin
- Animal Models of Exposure (liquid or vapor)
- Lung – Intratracheal or inhalation
- Parenteral
- In vivo Safety and Efficacy Studies
- Inhalation, intranasal, Dermal, Intramuscular, Intravenous, Intraperitoneal, and Subcutaneous routes of exposure
- Animal model development
- Plethysmography/Spirometry
- Telemetry and Physiology
- Assay Development And Validation
- Pharmacokinetics
- PK Assay Development
- Dose-ranging Studies
- Safety Studies
- Histology and Pathology
- Blood Chemistry and Hematology Studies
- Customized study designs and alternative animal models
- Biomarkers of toxicity
- Cholinesterase inhibition
- Cell-based Toxicity Assays
- Cytotoxicity (high throughput)
- Transcriptomics/Proteomics
- Metabolomics
- Category A,B,& C Bacterial Pathogens
- Foodborne Bacterial Pathogens
- Multi-Drug Resistance (MDR) and Pathogens
- Other Tier 1 HHS and USDA Select Agents and Toxins
Experience specific to influenza virus, including highly pathogenic Avian influenza virus (HPAIV ) Influenza: (H1N1, H5N1, H7N9, H3N2, B), Encephalitis viruses, Hemorrhagic Fever Viruses include:
- All necessary permits, licensing, and certifications to acquire, maintain, and work with viruses
- Existing stocks of seasonal, veterinary isolates, reverse genetics reassortants, vaccine, and H5N1 strains
- Preclinical toxicology to support vaccine development
Experience
- Evaluation of influenza POC diagnostics, including HPAI
- Ferret intranasal and bioaerosol challenge studies with H5N1 and H1N1 strain
- Mouse intranasal challenge with H5N1 and H1N1 strains
- Egg infectious dose and TCID50 in MDCK, MV1 Lu, and other cells
- Immunogenicity assays and ELISAs
- Isolation and titration of virus from infected tissues, organs, nasal washes, feces and rectal swabs
- Hemagglutination assays using human, guinea pig, horse, chicken, or turkey cells
- Hemagglutination inhibition assays using human or animal sera
Isolation, Culture, and Evaluation
- Human and animal influenza viruses (including highly pathogenic avian influenza virus)
- Food-borne and water-borne viruses (including enteroviruses)
- Anthropod-borne viruses (including West Nile Virus)
- CDC select agents (including the encephalitic alphaviruses and flaviviruses)
- Prion protein production (including hamster adapted scrapie strain 263K)
- Virus simulants (including empty capsid particles and alphavirus replicons)
- Development and maintenance of repositories
- Large scale production in static and suspension cultures
- Serology work including development and validation of ELISAs
- Microneutralization and plaque reduction neutralization assays
- Aerosol inhalation studies for various animal models including ferrets
Molecular Support
- Genomic sequencing of known and newly discovered RNA and DNA viruses (Including examples: GenBank Access # EF568607, EF571853, EF571854, EU081844)
- PCR assay design, development and validation, including reverse-transcriptase and real-time PCR assays
- Full genome cloning of RNA and small DNA viruses
Product Support
- Human and veterinary vaccine safety and efficacy studies
- Adventitious agent screening and validation of viral decontamination
- Viral clearance studies from cell culture derived products
- Prion clearance studies from plasma products
- Testing of live vaccine formulations, including pH, osmolality and Karl Fisher Tests)
Basic Research
- Vaccine design and development
- Development of animal challenge models (including aerosol exposures)
- Eukaryotic protein expression from viral vectors
- Antibody production
- Selection and characterization of viral mutants
- Assessment of viral evolution and quasispecies
- Literature searches and development of expert reviews
Specialized Facilities: Techniplast caging for optimal animal health and collection efficiency plus protection against cross-contamination
Vaccine development for both viral and bacterial pathogens, with focus on Biodefense and Emerging Pathogens or Threats:
- Animal Models of infection and pre-clinical testing
- Plaque titers, Virus neutralization
- Cell-based assays
Evaluation of Drugs and Therapeutics for both Biodefense and Industrial Applications Against Pathogenic Bacteria
- Infection models and natural histories
- Minimum Inhibitory Concentration (MIC) CLSI standards
- In vitro and In vivo Safety Studies
- Small Molecule and Peptide PK Assays & Analytical Methods
- In vivo Safety and Efficacy Studies: Inhalation, Intranasal, Dermal, Intramuscular, Intravenous, Intraperitoneal, and Subcutaneous routes of exposure
- Animal model development: Plethysmography/Spirometry, Telemetry and Physiology
- Assay Development and Validation: Pharmacokinetics, PK Assay Development, Dose Ranging Studies
- Safety Studies
- Histology and Pathology
- Blood Chemistry & Hematology
- Certified laboratories at BSL-2, BSL3, ABSL-2, ABSL-3
- Highly secure facilities, registered with the CDC and USDA for handling Tier 1 HHS and USDA Select Agents and Toxins (7 CFR Part 331, 9 CFR Part 121, and 42 CFR Part 73)
- Immunoassays: Cytokines, Serology
- Biomarkers of infection/toxicity
- Cell Based Assays: Neutralizing Ab, Cytotoxicity
- Molecular Assays: RTPCR, Next Gen Sequencing
We are different.
MRIGlobal stands apart from other research organizations. We offer both pre/nonclinical studies requiring high containment and relevant in vivo models and routes of exposure.